BERLIN, Germany — Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior...
Latest News
Houston, Texas – Triple-negative breast cancer (TNBC) is the subtype of breast cancer that is the hardest to treat. TNBC patients account for more than 20,000 cases of this condition annually in the U.S. alone. They experience worse outcomes than patients with other breast cancer subtypes – their five-year mortality...
Houston, TX – Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors. A team led by researchers at...
HOUSTON, TX – Researchers at Baylor College of Medicine and collaborating institutions have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings, published in Nature Cell Biology, show two distinct patterns of B cell abnormalities that could serve...
BOSTON – BBK Worldwide (BBK), the global leader in patient recruitment and engagement, announces that its RSG® Arrive travel program has achieved a major milestone with the completion of 20,000 trips. This program, which was launched in 2012 and continues to expand in response to marketplace needs, has made clinical trial participation...
ZURICH and NEWPORT BEACH, Calif. – BC Platforms (BCP), a global leader in healthcare data management, analytics, and access and CureDuchenne, a leading global non-profit organisation focused on finding and funding a cure for Duchenne muscular dystrophy, today announced a new collaboration. As part of the collaboration, CureDuchenne has integrated BCP’s Discovery and Research...
BUFFALO, NY- January 31, 2024 – A new research paper was published in Oncotarget’s Volume 15, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.” Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature...
Braunschweig, Germany – A new research paper was published in Oncotarget’s Volume 14 on December 1, 2023, entitled, “Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.” In multiple myeloma patients, high levels of soluble B-cell maturation antigen (sBCMA) can limit...
Best-corrected visual acuity (BCVA) changes and ocular symptoms may affect the management of belantamab mafodotin (belamaf) dosing among patients with relapsed or refractory multiple myeloma (RRMM), according to research presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Investigators conducted a post hoc investigation from the DREAMM-2 trial (ClinicalTrials.gov...
MINNEAPOLIS – Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership with Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to include supply chain services in support of the upcoming commercial launch of Libmeldy™ (autologous...